For children 6 months to less than five years old:
Community pharmacies cannot provide vaccines to children under five years old. Children under five will receive their immunizations through Public Health clinics. For more information about booking an appointment or available walk-in clinics, see the Government of Saskatchewan website, call 1-833-SASKVAX (1-833-727-5829) or book online.
Indigenous Services Canada and Northern Inter-Tribal Health Authority will also be offering vaccine clinics in First Nation and Métis communities.
For children five years and older:
COVID-19 vaccinations are available through participating pharmacies, pop-up clinics, and booked appointments. For more information, see the Government of Saskatchewan website.
Last Reviewed
08 Aug 2022
As of July 2022, Health Canada has approved the use of Moderna Spikevax™ vaccine for children 6 months to 5 years of age. This is the same Moderna Spikevax™ vaccine that is being given to older children (6 years and older) and adults but is a lower concentration (which means there is less active ingredient in each milliliter of vaccine) so that a lower dose can be given to children five and under.
In Saskatchewan, for children 6 months to under 5 years old, Moderna Spikevax™ will be offered. Vaccination of children under 5 years old is not available in Saskatchewan pharmacies.
Pfizer-BioNTech Comirnaty™ is not approved for children under the age of 5. Health Canada is still reviewing the information that Pfizer submitted for approval in Canada. A lower dose of Pfizer-BioNTech Comirnaty™ is approved for children under 5 in the United States.
For children 5 years of age and older, both Moderna Spikevax™ and Pfizer-BioNTech Comirnaty™ are approved for use. The next FAQ has more information about vaccines for kids 5 years of age and older.
References
- NACI: Recommendations on the use of the Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age; 14 July 2022
Last Reviewed
08 Aug 2022
Health Canada has approved the use of Pfizer-BioNTech Comirnaty™ and Moderna Spikevax™ for children 5 years of age and older.
Children aged 5 years up to 6 years can receive either Pfizer-BioNTech Comirnaty™ 10 mcg or Moderna Spikevax™ 25 mcg for the primary series, which means the first 2 doses (or 3 doses if immunocompromised). Pfizer-BioNTech Comirnaty™ is preferred to Moderna Spikevax™ because of more real-world experience with Comirnaty™, but Moderna Spikevax™ can still be given. Moderna Spikevax™ 25 mcg is not available at pharmacies.
Children aged 6 years to under 12 years can receive either Pfizer-BioNTech Comirnaty™ 10 mcg or Moderna Spikevax™ 50 mcg for the primary series, which means the first 2 doses (or 3 doses if immunocompromised). Pfizer-BioNTech Comirnaty™ is preferred to Moderna Spikevax™ because of more real-world experience with Comirnaty™, but Moderna Spikevax™ can still be given.
Children aged 5 years to under 12 years can receive Pfizer-BioNTech Comirnaty™ 10 mcg for booster doses. Moderna Spikevax™ is not to be used for booster doses in this age group.
References
- Canadian Immunization Guide
- COVID-19 Vaccine Contraindications & Precautions Background Document
- Available at eHealth COVID-19 Immunization Manual
Last Reviewed
06 Sep 2022
Fortunately, COVID-19 has spared the majority of children from getting really sick. However, there have been children who have gotten very ill from the virus. The risk may be lower, but the risk is still there, and COVID-19 infection can be scary.
The benefit of vaccines is that our children can get protection without having to risk the serious consequences of getting sick with COVID-19.
In older children and adults, vaccines offer protection from severe outcomes like hospitalization and death.
COVID-19 can cause long-term effects in children. Research from the UK suggested that approximately 1 in 10 school-aged children had symptoms for more than 4 weeks after being infected with COVID-19.
COVID-19 may lead to multisystem inflammatory syndrome in children (MIS-C) – a condition where different parts of the body become inflamed. It’s rare, but it can happen.
Severe outcomes aren’t predictable and can occur in healthy children. Many children that have been hospitalized had no pre-existing health conditions.
Vaccination is a safe way of protecting kids from the risks of COVID-19 infection.
Check out this infographic from our colleagues at the University of Waterloo and the Health Canada website for more information.
References
- Canadian Immunization Guide. COVID-19 vaccine. 21 June 2022.
- NACI: Recommendations on the use of the Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age; 14 July 2022
- Health Canada. Vaccines for children: COVID-19. Updated 14 July 2022. Available from: https://www.canada.ca/en/public-health/services/vaccination-children/covid-19.html
- Kids Health First. COVID-19 Vaccines for Youth. Cited 8 Nov 2021. Available from: https://kidshealthfirst.ca/?utm_source=link.cep.health&utm_medium=urlshortener&utm_campaign=vaccines
- Office for National Statistics United Kingdom. (2021) Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. Retrieved from Office for National Statistics’ website. [Updated 4 Nov 2021; cited 8 Nov 2021]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/4november2021
- Office for National Statistics United Kingdom. (2021) Coronavirus (COVID-19) latest insights: Infections. Retrieved from Office for National Statistics’ website. [Cited 8 Nov 2021]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/infections#long-covid
Last Reviewed
08 Aug 2022
Yes, children who have had COVID-19 should still get the vaccine. Based on what we know from older kids and adults, there is some protection that comes from getting an infection, but this protection starts to go away after a couple of months. Protection from an infection AND vaccination is stronger and lasts longer.
There is evidence that waiting a bit after infection before receiving a COVID-19 vaccine dose may mean a better response to the vaccine. The National Advisory Committee on Immunization (NACI) suggests that most children wait 8 weeks after a COVID-19 infection (from first day of symptoms or first positive test) to get a COVID-19 vaccine. For children who are moderately to severely immunocompromised, this interval may be shortened to 4-8 weeks. Children who have had MIS-C (See “What is MIS-C” below for more information) should wait until MIS-C has cleared or at least 90 days after MIS-C began, whichever is later.
In Saskatchewan, older children (5 years and up) and adults are able to get a COVID-19 vaccine as soon as symptoms are better and they are no longer infectious. Children 6 months to 5 years receiving Moderna Spikevax™ may still be advised to wait 4-8 weeks after COVID-19 infection depending on vaccine supply – check with your vaccine provider.
References
- Canadian Immunization Guide. COVID-19. 21 June 2022.
- NACI. Recommendations on the use of the Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age. 14 July 2022.
- eHealth COVID-19 Immunization Manual: COVID-19 Vaccine Contraindications and Precautions Background Document
- Directive from Dr. Julie Kryzanowski, Deputy Chief Medical Health Officer. 20 Jul 2022.
Last Reviewed
08 Aug 2022
- The pediatric COVID-19 vaccines can be given at the same time or any time before or after other vaccines.
- If more than one vaccine is given at the same time, they'll be given at different sites.
- For children 6 months to 5 years of age getting Moderna Spikevax™, NACI recommends getting the COVID-19 vaccine 14 days before or after other vaccines. This is to make it easier to figure out a possible cause if side effects happen. However, it may be ok to give the COVID-19 vaccine with other vaccines so that children don’t miss out on getting vaccinated.
References
- Canadian Immunization Guide. COVID-19. 21 June 2022.
- NACI. Recommendations on the use of the Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age. 14 July 2022.
- eHealth COVID-19 Immunization Manual: COVID-19 Vaccine Contraindications and Precautions Background Document
- Directive from Dr. Julie Kryzanowski, Deputy Chief Medical Health Officer. 20 Jul 2022
Last Reviewed
08 Aug 2022
Both myocarditis and pericarditis have been reported with COVID-19 mRNA vaccination.
Myocarditis is inflammation of the heart muscle and pericarditis is inflammation of the lining around the heart.
Cases that have been reported with COVID-19 vaccination tend to be:
- More often after the second dose.
- Usually within a week after vaccination.
- More often in males than females and more often in 12-30 years old.
- Highest incidence in males aged 16-17 years old. Risk decreases in occurrence down to age 12, therefore, risk in 5-11 year olds is expected to be lower.
Early data suggests a higher rate reported after vaccination with Moderna compared to Pfizer, but the research is ongoing. This may be due to the difference in doses. Data from older age groups also suggests that an interval longer than 21 days between 1st and 2nd dose may also be associated with a reduced risk of myocarditis.
Myocarditis and pericarditis can be caused by a number of things including viral infection, bacterial infection, health conditions, and other medications.
We have learned that there are different types of myocarditis:
- classic myocarditis or “pre COVID-19” myocarditis
- COVID-19 infection related myocarditis
- MIS-C myocarditis – MIS-C is an inflammatory illness that has been associated with COVID-19 infection
- COVID-19 vaccine related myocarditis
COVID-19 vaccine related myocarditis tends to have milder symptoms and resolves much more quickly than the other types of myocarditis. It is treated with anti-inflammatory medications, and hospitalizations are usually short (a day or so) and usually just to keep an eye on the patient. The risk of damage to the heart is much greater with COVID-19 infection myocarditis than it is with vaccine related myocarditis.
There are a few reasons why kids 5-11 years old might be at a lower risk for myocarditis:
- Lower incidence in 12-15 years olds versus 16-17 year olds.
- Lower dose – we are unsure if dose is related to risk of myocarditis, but it may explain why more cases have been seen with Moderna/Spikevax compared to Pfizer/Comirnaty.
- Testosterone is thought to play a role in myocarditis. Since younger kids haven’t hit puberty, this may mean a lower risk.
We have also learned about the symptoms to watch out for and when to seek medical attention. The symptoms include chest pain, shortness of breath and heart palpitations. With medical attention, most people that developed myocarditis following COVID-19 vaccination had a quick recovery.
When considering the risk of myocarditis, it is important to consider the risk of developing myocarditis from COVID-19 infection. The risk of myocarditis with COVID-19 infection may be as high as 450 cases per million infections in males aged 12-17. The rate of myocarditis with mRNA vaccine in 12-17 yo males is around 66.7 cases per million doses.
Myocarditis can be a scary risk, but it is a very small risk and manageable risk.
References
- NACI: Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5-11 years of age
- NACI: Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age.
- FDA Briefing document. Vaccines and Related Biological Products Advisory Committee Meeting October 26, 2021.
- Patel T, Kelleman M, West Z, et al. Comparison of MIS-C Related Myocarditis, Classic Viral Myocarditis, and COVID-19 Vaccine related Myocarditis in Children. medRxiv. 2021 Jan 1.
- Singer ME, Taub IB, Kaelber DC. Risk of myocarditis from COVID-19 infection in people under age 20: a population-based analysis. medRxiv. 2021 Jan 1.
- Edward Nirenberg on Twitter. 5 Nov 2021. Available from: https://twitter.com/ENirenberg/status/1456668682730475527?s=20
- Dr. A Kurji, Dr. M Brindamour, Dr. M Sarda. Safe Schools Saskatchewan. Children and Vaccines Town Hall Oct 13, 2021. Available from: https://youtu.be/bmg_OdgOXI8
- Myocarditis and Pericarditis after mRNA vaccination for COVID-19. Available from: https://www.ontariofamilyphysicians.ca/tools-resources/covid-19-resources/covid-19-vaccines/myocarditis-after-mrna.pdf
Last Reviewed
19 Nov 2021
- Multisystem Inflammatory Syndrome in Children (MIS-C) is an illness where different body parts can become inflamed, including the heart, lungs, kidneys, brain, skin, eyes, or gastrointestinal tract. This has also been reported in adults (MIS-A).
- MIS-C has been associated with COVID-19 infection. It generally occurs about 4 weeks after infection with COVID-19. The initial symptoms include fever, rash, diarrhea, and vomiting.
- MIS-C is rare and treatable. Most kids that get it will eventually get better with medical care, but it can make some kids very sick and be quite dangerous.
- MIS-C usually affects school-age children.
- MIS-C is a possible complication of COVID-19 infection that parents and caregivers should consider when weighing the risk versus benefit of vaccination. Vaccination is a safe way of preventing COVID-19 infection and the possible complications associated with COVID-19 infection.
- MIS-C was one of the rare adverse effects that was being monitored in the clinical trials that were done when testing the COVID-19 vaccine in kids; no cases were reported in the trials but we needed more information as this is rare. From real-world data, there have been very rare cases following COVID-19 vaccine reported outside of the trials, but we can’t say that the vaccine caused the MIS-C.
References
- Centers for Disease Control and Prevention. For Parents: Multisystem Inflammatory Syndrome in Children (MIS-C) associated with COVID-19. 20 Sept 2021. Available from: https://www.cdc.gov/mis/mis-c.html
- Johns Hopkins Medicine. MIS-C and COVID-19: Rare Inflammatory Syndrome in Kids and Teens. 8 Jul 2021. https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/misc-and-covid19-rare-inflammatory-syndrome-in-kids-and-teens
- Canadian Immunization Guide: COVID-19 Vaccine
- NACI. Summary of updates in the Canadian Immunization Guide of June 3, 2022: Updated guidance on COVID-19 vaccines in Canada. Government of Canada: Ottawa, ON. [03 Jun 2022; cited 11 Jul 2022]. Available from: https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-updates-canadian-immunization-guide-june-3-2022-covid-19-vaccines.html
Last Reviewed
11 Jul 2022
Yes. Symptoms of long COVID include fatigue, muscle and joint pain, headache, trouble sleeping, trouble concentrating, and cough. Research from the UK suggested that approximately 1 in 10 school aged children had symptoms for more than 4 weeks after being infected with COVID-19, and 7-8% of children with COVID-19 reported symptoms longer than 12 weeks after being diagnosed. Long COVID can occur after both mild and severe infections. Long COVID can affect mental health, day-to-day function, and school attendance.
The risk of long COVID is a reason to consider vaccination.
References
- Thomson H. Children with long covid. New Sci. 2021 Feb 27;249(3323):10-11. doi: 10.1016/S0262-4079(21)00303-1. Epub 2021 Mar 3. PMID: 33686318; PMCID: PMC7927578.
- Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. The Lancet Child & Adolescent Health. 2021 Jun 1;5(6):e22-3.
- Office for National Statistics United Kingdom. (2021) Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK. Retrieved from Office for National Statistics’ website: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/4november2021
- Office for National Statistics United Kingdom. (2021) Coronavirus (COVID-19) latest insights: Infections. Retrieved from Office for National Statistics’ website: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19latestinsights/infections#long-covid
Last Reviewed
18 Nov 2021
There has been a lot of information shared about something called VITT, which is vaccine induced immune thrombotic thrombocytopenia, and it's a condition of blood clots plus low platelets, that occurs following viral vector vaccines. In Canada, the viral vector vaccines are AstraZeneca, COVISHIELD, and Johnson and Johnson. There haven't been any reports of blood clots with low platelets or VITT reported in people that have received mRNA vaccines, like the Pfizer COVID-19 vaccine. There have been blood clots reported, but at a similar rate to what the usual occurrence of blood clots is. Getting an mRNA vaccine, like the Pfizer vaccine does not put anyone at a higher risk for blood clots.
Reference
- NACI: Recommendations on the use of COVID-19 vaccines under the COVID-19 tab
Last Reviewed
18 Nov 2021
- No, vaccines do not impact fertility and do not affect the reproductive system. There was a myth circulating on the internet that the spike protein in the COVID-19 vaccines is similar to a protein in the placenta, but this is not true. mRNA vaccines have been studied in pregnancy, and there isn’t a higher risk of miscarriage or negative pregnancy outcomes.
- There have been reports of menstrual cycle disruption, and what is important to note is that the menstrual cycle can be affected by many things, including infections and stress. Studies have shown that there are not more menstrual cycle irregularities in people that have received the COVID-19 vaccine compared to the general population.
- The SOCG of Canada has excellent information:
- Dr. Jennifer Gunter, and OBGYN, has shared some excellent facts about this as well:
- If you want a review of the evidence:
Last Reviewed
18 Nov 2021
Long term side effects are very unlikely to occur because of how our immune system works and because of how vaccines work. The use of vaccines can be traced back to the 18th century and many of the vaccines we use today have been in use for decades. And yes, COVID-19 mRNA vaccines are new, but researchers have been studying mRNA vaccines for flu, Zika, rabies, and cytomegalovirus. The first use of an mRNA vaccine can be traced back to the early 1990’s. mRNA technology is also used in cancer treatment research.
Here’s a few key points about long term vaccine side effects:
- Most of the ingredients in vaccines break down very quickly, and do not stick around in the body.
- Most side effects occur because our immune system is responding to the vaccine.
- Most side effects occur within the first 6-8 weeks after vaccination.
- Vaccines are continually being monitored on many different levels including further research and ongoing surveillance. When rare side effects happen, they are identified and responded to.
References
- Scienceupfirst. Concerned about Long-Term Side Effects of the COVID-19 vaccines? 2 Nov 2021. Available from: https://www.instagram.com/p/CVx2_D7rmzD/?utm_source=ig_web_copy_link
- Centers for Disease Prevention and Control. Understanding mRNA COVID-19 Vaccines. 3 Nov 2021. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html
- Plotkin S. History of vaccination. Proc Natl Acad Sci U S A. 2014 Aug 26;111(34):12283-7. doi: 10.1073/pnas.1400472111. Epub 2014 Aug 18. PMID: 25136134; PMCID: PMC4151719.
- Kim YK. RNA Therapy: Current Status and Future Potential. Chonnam Medical Journal. 2020 May;56(2):87-93. DOI: 10.4068/cmj.2020.56.2.87. PMID: 32509554; PMCID: PMC7250668.
- Stone Jr CA, Rukasin CR, Beachkofsky TM, Phillips EJ. Immune‐mediated adverse reactions to vaccines. British journal of clinical pharmacology. 2019 Dec;85(12):2694-706.
Last Reviewed
18 Nov 2021
No. Vaccines cannot replicate (or make copies of) the coronavirus. Vaccines only provide instructions to our bodies to make the spike protein that is present on the virus, but they do not actually make the virus.
Viruses constantly change through mutation. These changes lead to variants of the original virus – some variants disappear quickly while others have advantages that cause them to stick around. Variants develop when the virus infects someone, and then starts to replicate (or make copies of) itself. Mutations (or mistakes) can happen when these copies are being made, which leads to a variant of the original virus. Variants can develop when the virus is able to spread and replicate quickly. More infections = more replication = more mutations = more variants. The way to stop the development of variants is to stop the spread of the virus.
References
- Dr. A Kurji, Dr. M Brindamour, Dr. M Sarda. Safe Schools Saskatchewan. Children and Vaccines Town Hall Oct 13, 2021. Available from: https://youtu.be/bmg_OdgOXI8
- Centers for Disease Control and Prevention. COVID-19. What you Need to Know about Variants. 1 Nov 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant.html
Last Reviewed
18 Nov 2021
- Talk to your children. Start having the conversations with your younger children if you haven’t already. By giving them the information first, you get control over the information they are receiving.
- Give your children age-appropriate information about the “W’s” of COVID-19 and vaccines:
- What is COVID, what’s happening in our province and country and world with COVID-19
- Why we give vaccines
- Who else has received vaccines
- Where they will be able to get a vaccine and when it might be their turn
- Encourage children to come home and talk to you about what they hear at school and from other friends or families.
- Don't dismiss what your child is saying to you. Validate their concerns, have a discussion, and answer their questions. Kids that don’t feel like we're answering their questions may not come to us with more questions as they get older.
- Be curious and find information together. If you don't know the answer or are hearing rumors, look it up together using trustworthy resources. This teaches our children how to find safe information in general. Make sure to use a reputable source: ask experts that you trust. An option is to book an appointment with their family doctor or pediatrician to talk about it so that they're getting that information from a safe and trusted source.
- Kids Health First: https://kidshealthfirst.ca/pages/parents-and-caregivers
- About Kids Health: https://www.aboutkidshealth.ca/Article?contentid=3937&language=English
- Canadian Paediatric Society: https://caringforkids.cps.ca/handouts/immunization/covid-19-vaccine-for-children
- Immunize Canada: https://immunize.ca/covid-19-info
- Health Canada
Reference
- Dr. A Kurji, Dr. M Brindamour, Dr. M Sarda. Safe Schools Saskatchewan. Children and Vaccines Town Hall Oct 13, 2021. Available from: https://youtu.be/bmg_OdgOXI8
Last Reviewed
18 Nov 2021
Here are some excellent resources to help:
- The CARD system is a 4 step system (get Comfortable, Ask questions, Relax, Distract) to help cope before and during vaccination: https://immunize.ca/card-parents
- The Comfort Promise Learning hub from Sick Kids hospital has information about managing needle pain: https://www.aboutkidshealth.ca/comfortpromise
- Solutions for Kids in Pain has YouTube videos on how to “prepare for the poke”: https://kidsinpain.ca/
- SKIP also has a compilation of resources from other agencies: https://kidsinpain.ca/wp-content/uploads/2022/07/NeedlePainVaccine-under-5.pdf
- Children's Healthcare Canada collaboration with medSask and CPhA checklist for vaccinating infants and children
Last Reviewed
8 Aug 2022
Check out the Immunize Canada website for information on what can be done and what can be given to help with vaccine pain. Click on the links below:
For more information about using numbing creams, click on the links below:
Last Reviewed
8 Aug 2022
References
- Doctors Manitoba. Were fetal cells used in the COVID-19 vaccine’s development? Available from: https://www.manitobavaccine.ca/answers/were-fetal-cells-used-in-the-covid-19-vaccines-development/
- Immunize BC. Frequently Asked Questions – Are human fetal cells used to make some vaccines? 8 Jul 2021. Available from: https://immunizebc.ca/ask-us/questions/are-human-fetal-cells-used-make-some-vaccines
Last Reviewed
18 Nov 2021
- In answering this question, it's important to understand the science behind mRNA vaccines. The mRNA vaccines work similarly to other vaccines that are being used today. Vaccines help our immune system to recognize viruses so that our bodies are better able to respond to the threat of an infection.
- To understand how vaccines work, it helps to understand how infections work. When someone gets a virus, the virus infects the other cells in our body and as part of the invasion, the virus causes our cells to make more and more virus. Our immune system starts to recognize the virus as foreign, and attacks against the virus. We recover from the virus but our immune system keeps a memory of what happened so that if it sees the virus again, it can remember how to attack and prevent the virus from causing severe infection.
- COVID-19 has a protein on the outside of it called the spike protein, and that is what allows it to get into our cells. The spike protein is what makes COVID-19 especially infectious. Scientists saw this spike protein as a good target for our immune systems to recognize when they started to look at making a vaccine.
- What is a bit different from other vaccines that are being used today is the use of mRNA in some COVID-19 vaccines. The use of mRNA isn’t new: scientists have been researching how mRNA can be used in medicine for many years. In fact, research into using mRNA specifically for vaccines started as early as the 1990s and the first clinical trial of an mRNA vaccine started in 2006.
- mRNA is messenger RNA, it's not DNA, and it doesn't combine with DNA to change genetics. Rather, it's a messenger, so it's like an email or a text message being sent to your body to turn on the immune system. The mRNA in the COVID-19 vaccines serves as a very specific email or message with specific instructions on how to make the spike protein. The mRNA enters immune cells, the cells read the instructions and make the protein. Our immune system recognises these proteins as foreign and responds by sending out antibodies. These antibodies are what protect us. Our body remembers the protein and how it responded with antibodies, which is typically what our immune system does anytime it comes across something foreign, whether it is from an infection or a vaccine. This process teaches our body how to respond if we actually come into contact with the COVID-19 virus, and we can mount that immune response.
- The immune response to a COVID-19 vaccine is similar to what would happen if we actually got an infection. The difference is that the vaccine doesn’t come with the symptoms and potential complications that an infection with COVID-19 does.
- The mRNA in COVID-19 vaccines is very specific to only make this specific spike protein. The mRNA doesn’t enter the part of our cells where DNA is stored. And the thing about mRNA is that it doesn't stick around in the body. It isn't very stable. It breaks down very quickly and within two to three days, it's gone from the body. Long term complications are not possible because the mRNA and all the other vaccine components are quickly eliminated from the body, and the only thing that remains is our immune system memory.
References
- Dr. A Kurji, Dr. M Brindamour, Dr. M Sarda. Safe Schools Saskatchewan. Children and Vaccines Town Hall Oct 13, 2021. Available from: https://youtu.be/bmg_OdgOXI8
- Centers for Disease Control and Prevention. Understanding mRNA COVID-19 Vaccines. 3 Nov 2021. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html
- Kim YK. RNA therapy: current status and future potential. Chonnam medical journal. 2020 May;56(2):87.
- Weide B, Carralot JP, Reese A, et al. Results of the first phase I/II clinical vaccination trial with direct injection of mRNA. Journal of immunotherapy. 2008 Feb 1;31(2):180-8.
Last Reviewed
18 Nov 2021